Since we launched our first IVD test kit in 1966 our products have consistently been recognized by the market for their excellence.
We have carried out a number of successful acquisitions of best-in-class IVD companies over the years (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010).
This has further reinforced the know-how in our group and bolstered our capacity to innovate, develop, produce and deliver products of only the highest quality.
Products by diseases and disorders:
News & EventsView all news & upcoming events
iAMP® COVID-19 Detection kit, a molecular SARS-CoV-2 detection assay distributed by Fujirebio Europe, is now CE marked
Fujirebio Europe launches the automated Lumipulse® G SCC assay for the quantitative measurement of squamous cell carcinoma antigen
Fujirebio Europe launches iAMP® COVID-19, a new molecular detection assay that eliminates the need for RNA extraction
Fujirebio Europe launches the RoboBlot™ Non-Heated instrument for high throughput INNO-LIA® Score assay automation
Pioneering the future of healthcare
We are part of Miraca Group, a global Japanese healthcare player that favors cross-group R&D synergies and expertise in clinical laboratory testing (SRL), IVD testing solutions (Fujirebio) and other specialized healthcare related activities.
As part of Miraca Group we have the capacity to truly understand the patient needs.
We collaborate closely with clinicians and laboratorians worldwide to develope innovative IVD testing solutions for today and tomorrow.
A global partner of choice
Today, we sell our products in more than 100 countries worldwide.
We have offices in the United States, Latin America, Europe and Asia, and are supported by an international distribution network and leading OEMs.
Our proven commitment to manufacturing quality has earned us a strong reputation with our direct customers, and global partners at leading diagnostic companies.
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
Automation is an important step in the direction of more standardization as it limits the number of manual handling steps and therefore minimizes...
Mar 16, 2020
CSF Aβ1-42/Aβ1-40 is a tool to normalize values of patients with different amyloid levels, as other ratios might be seen more as interpretation tools...
Mar 2, 2020